{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T06:39:34Z","timestamp":1792132774334,"version":"4.4.0"},"reference-count":129,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,9,1]],"date-time":"2019-09-01T00:00:00Z","timestamp":1567296000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,9,1]],"date-time":"2019-09-01T00:00:00Z","timestamp":1567296000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pharmacological Research"],"published-print":{"date-parts":[[2019,9]]},"DOI":"10.1016\/j.phrs.2019.104354","type":"journal-article","created":{"date-parts":[[2019,7,12]],"date-time":"2019-07-12T11:56:21Z","timestamp":1562932581000},"page":"104354","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":43,"special_numbering":"C","title":["Effects of biological and targeted synthetic DMARDs on bone loss in rheumatoid arthritis"],"prefix":"10.1016","volume":"147","author":[{"given":"Giovanni","family":"Orsolini","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angelo","family":"Fassio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maurizio","family":"Rossini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanni","family":"Adami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandro","family":"Giollo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristian","family":"Caimmi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luca","family":"Idolazzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ombretta","family":"Viapiana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Davide","family":"Gatti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"8","key":"10.1016\/j.phrs.2019.104354_bib0005","doi-asserted-by":"crossref","first-page":"2219","DOI":"10.1002\/art.27510","article-title":"Generalized bone loss as a predictor of three-year radiographic damage in African American patients with recent-onset rheumatoid arthritis","volume":"62","author":"Zhang","year":"2010","journal-title":"Arthritis Rheum."},{"issue":"3","key":"10.1016\/j.phrs.2019.104354_bib0010","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1136\/ard.2007.086348","article-title":"Changes in hand and generalised bone mineral density in patients with recent-onset rheumatoid arthritis","volume":"68","author":"Guler-Yuksel","year":"2009","journal-title":"Ann. Rheum. Dis."},{"issue":"12","key":"10.1016\/j.phrs.2019.104354_bib0015","first-page":"2590","article-title":"Reduced bone mineral density in early rheumatoid arthritis is associated with radiological joint damage at baseline and after 2 years in women","volume":"30","author":"Forslind","year":"2003","journal-title":"J. Rheumatol."},{"issue":"6","key":"10.1016\/j.phrs.2019.104354_bib0020","doi-asserted-by":"crossref","first-page":"997","DOI":"10.3899\/jrheum.100829","article-title":"Relationship of focal erosions, bone mineral density, and parathyroid hormone in rheumatoid arthritis","volume":"38","author":"Rossini","year":"2011","journal-title":"J. Rheumatol."},{"issue":"10","key":"10.1016\/j.phrs.2019.104354_bib0025","doi-asserted-by":"crossref","first-page":"e70","DOI":"10.1136\/annrheumdis-2016-210022","article-title":"Denosumab, cortical bone and bone erosions in rheumatoid arthritis","volume":"75","author":"Rossini","year":"2016","journal-title":"Ann. Rheum. Dis."},{"issue":"10","key":"10.1016\/j.phrs.2019.104354_bib0030","doi-asserted-by":"crossref","first-page":"2142","DOI":"10.1002\/jbmr.3209","article-title":"Osteoporosis: an independent determinant of bone erosions in rheumatoid arthritis?","volume":"32","author":"Rossini","year":"2017","journal-title":"J. Bone Miner. Res."},{"issue":"5","key":"10.1016\/j.phrs.2019.104354_bib0035","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1007\/s00223-017-0373-1","article-title":"Bone loss in rheumatoid arthritis: basic mechanisms and clinical implications","volume":"102","author":"Shim","year":"2018","journal-title":"Calcif. Tissue Int."},{"issue":"4","key":"10.1016\/j.phrs.2019.104354_bib0040","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1016\/j.bbrc.2007.04.042","article-title":"Human CD4+CD25+ regulatory T cells inhibit the differentiation of osteoclasts from peripheral blood mononuclear cells","volume":"357","author":"Kim","year":"2007","journal-title":"Biochem. Biophys. Res. Commun."},{"issue":"12","key":"10.1016\/j.phrs.2019.104354_bib0045","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1038\/nrrheum.2009.217","article-title":"Osteoimmunology and the effects of the immune system on bone","volume":"5","author":"Takayanagi","year":"2009","journal-title":"Nat. Rev. Rheumatol."},{"issue":"6812","key":"10.1016\/j.phrs.2019.104354_bib0050","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1038\/35046102","article-title":"T-cell-mediated regulation of osteoclastogenesis by signalling cross-talk between RANKL and IFN-gamma","volume":"408","author":"Takayanagi","year":"2000","journal-title":"Nature"},{"issue":"12","key":"10.1016\/j.phrs.2019.104354_bib0055","doi-asserted-by":"crossref","first-page":"4104","DOI":"10.1002\/art.23138","article-title":"Treg cells suppress osteoclast formation: a new link between the immune system and bone","volume":"56","author":"Zaiss","year":"2007","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.phrs.2019.104354_bib0060","doi-asserted-by":"crossref","first-page":"36","DOI":"10.2119\/molmed.2012.00058","article-title":"IL-1beta inhibits human osteoblast migration","volume":"19","author":"Hengartner","year":"2013","journal-title":"Mol. Med."},{"issue":"4","key":"10.1016\/j.phrs.2019.104354_bib0065","doi-asserted-by":"crossref","first-page":"2695","DOI":"10.1074\/jbc.M106339200","article-title":"Expression of the osteoblast differentiation factor RUNX2 (Cbfa1\/AML3\/Pebp2alpha A) is inhibited by tumor necrosis factor-alpha","volume":"277","author":"Gilbert","year":"2002","journal-title":"J. Biol. Chem."},{"issue":"3","key":"10.1016\/j.phrs.2019.104354_bib0070","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1016\/j.bbagen.2013.12.013","article-title":"Effect of TNFalpha on osteoblastogenesis from mesenchymal stem cells","volume":"1840","author":"Kotake","year":"2014","journal-title":"Biochim. Biophys. Acta"},{"issue":"1","key":"10.1016\/j.phrs.2019.104354_bib0075","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1002\/jbmr.5650110113","article-title":"Interleukin-6 and soluble interleukin-6 receptors in the synovial fluids from rheumatoid arthritis patients are responsible for osteoclast-like cell formation","volume":"11","author":"Kotake","year":"1996","journal-title":"J. Bone Miner. Res."},{"issue":"9","key":"10.1016\/j.phrs.2019.104354_bib0080","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1172\/JCI5703","article-title":"IL-17 in synovial fluids from patients with rheumatoid arthritis is a potent stimulator of osteoclastogenesis","volume":"103","author":"Kotake","year":"1999","journal-title":"J. Clin. Invest."},{"issue":"5","key":"10.1016\/j.phrs.2019.104354_bib0085","doi-asserted-by":"crossref","first-page":"2655","DOI":"10.4049\/jimmunol.170.5.2655","article-title":"IL-17 promotes bone erosion in murine collagen-induced arthritis through loss of the receptor activator of NF-kappa B ligand\/osteoprotegerin balance","volume":"170","author":"Lubberts","year":"2003","journal-title":"J. Immunol."},{"issue":"2","key":"10.1016\/j.phrs.2019.104354_bib0090","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1172\/JCI200523394","article-title":"IL-1 mediates TNF-induced osteoclastogenesis","volume":"115","author":"Wei","year":"2005","journal-title":"J. Clin. Invest."},{"issue":"3","key":"10.1016\/j.phrs.2019.104354_bib0095","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1038\/nrrheum.2017.213","article-title":"Updating osteoimmunology: regulation of bone cells by innate and adaptive immunity","volume":"14","author":"Walsh","year":"2018","journal-title":"Nat. Rev. Rheumatol."},{"issue":"4","key":"10.1016\/j.phrs.2019.104354_bib0100","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1007\/s11914-009-0023-2","article-title":"Proinflammatory cytokines and osteoporosis","volume":"7","author":"McLean","year":"2009","journal-title":"Curr. Osteoporos. Rep."},{"issue":"9","key":"10.1016\/j.phrs.2019.104354_bib0105","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0044552","article-title":"Estrogen deficiency induces the differentiation of IL-17 secreting Th17 cells: a new candidate in the pathogenesis of osteoporosis","volume":"7","author":"Tyagi","year":"2012","journal-title":"PLoS One"},{"issue":"2","key":"10.1016\/j.phrs.2019.104354_bib0110","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1002\/jcp.22159","article-title":"Regulation of adult bone turnover by sex steroids","volume":"224","author":"Frenkel","year":"2010","journal-title":"J. Cell. Physiol."},{"issue":"2","key":"10.1016\/j.phrs.2019.104354_bib0115","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1677\/joe.0.1720387","article-title":"Effects of oestrogen deprivation on interleukin-6 production by peripheral blood mononuclear cells of postmenopausal women","volume":"172","author":"Rachon","year":"2002","journal-title":"J. Endocrinol."},{"issue":"2","key":"10.1016\/j.phrs.2019.104354_bib0120","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1038\/nm1538","article-title":"Dickkopf-1 is a master regulator of joint remodeling","volume":"13","author":"Diarra","year":"2007","journal-title":"Nat. Med."},{"issue":"2","key":"10.1016\/j.phrs.2019.104354_bib0125","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1007\/s00223-013-9749-z","article-title":"Involvement of WNT\/beta-catenin signaling in the treatment of osteoporosis","volume":"93","author":"Rossini","year":"2013","journal-title":"Calcif. Tissue Int."},{"issue":"5","key":"10.1016\/j.phrs.2019.104354_bib0130","doi-asserted-by":"crossref","first-page":"821","DOI":"10.3899\/jrheum.100089","article-title":"Circulating Dickkopf-1 is correlated with bone erosion and inflammation in rheumatoid arthritis","volume":"38","author":"Wang","year":"2011","journal-title":"J. Rheumatol."},{"issue":"1","key":"10.1016\/j.phrs.2019.104354_bib0135","first-page":"77","article-title":"In patients with rheumatoid arthritis, Dickkopf-1 serum levels are correlated with parathyroid hormone, bone erosions and bone mineral density","volume":"33","author":"Rossini","year":"2015","journal-title":"Clin. Exp. Rheumatol."},{"issue":"9","key":"10.1016\/j.phrs.2019.104354_bib0140","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1038\/ncprheum0881","article-title":"The role of Wnt proteins in arthritis","volume":"4","author":"Schett","year":"2008","journal-title":"Nat. Clin. Pract. Rheumatol."},{"issue":"12","key":"10.1016\/j.phrs.2019.104354_bib0145","doi-asserted-by":"crossref","first-page":"2152","DOI":"10.1136\/ard.2010.132852","article-title":"Neutralisation of Dkk-1 protects from systemic bone loss during inflammation and reduces sclerostin expression","volume":"69","author":"Heiland","year":"2010","journal-title":"Ann. Rheum. Dis."},{"issue":"3","key":"10.1016\/j.phrs.2019.104354_bib0150","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1038\/nrrheum.2014.198","article-title":"Alternative pathways of osteoclastogenesis in inflammatory arthritis","volume":"11","author":"Adamopoulos","year":"2015","journal-title":"Nat. Rev. Rheumatol."},{"issue":"4","key":"10.1016\/j.phrs.2019.104354_bib0155","doi-asserted-by":"crossref","first-page":"R103","DOI":"10.1186\/ar2749","article-title":"Antibodies to cyclic citrullinated protein and erythrocyte sedimentation rate predict hand bone loss in patients with rheumatoid arthritis of short duration: a longitudinal study","volume":"11","author":"Boyesen","year":"2009","journal-title":"Arthritis Res. Ther."},{"issue":"1","key":"10.1016\/j.phrs.2019.104354_bib0160","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1080\/03009740510017986","article-title":"Comparison of dual X\u2010ray absorptiometry (DXA), digital X\u2010ray radiogrammetry (DXR), and conventional radiographs in the evaluation of osteoporosis and bone erosions in patients with rheumatoid arthritis","volume":"34","author":"Jensen","year":"2009","journal-title":"Scand. J. Rheumatol."},{"issue":"10","key":"10.1016\/j.phrs.2019.104354_bib0165","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1136\/ard.2003.015065","article-title":"Hand cortical bone mass and its associations with radiographic joint damage and fractures in 50\u201370 year old female patients with rheumatoid arthritis: cross sectional Oslo-Truro-Amsterdam (OSTRA) collaborative study","volume":"63","author":"Haugeberg","year":"2004","journal-title":"Ann. Rheum. Dis."},{"issue":"4","key":"10.1016\/j.phrs.2019.104354_bib0170","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1136\/annrheumdis-2015-208093","article-title":"Identification of a novel chemokine-dependent molecular mechanism underlying rheumatoid arthritis-associated autoantibody-mediated bone loss","volume":"75","author":"Krishnamurthy","year":"2016","journal-title":"Ann. Rheum. Dis."},{"issue":"1","key":"10.1016\/j.phrs.2019.104354_bib0175","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1093\/rheumatology\/keh414","article-title":"Localization of peptidylarginine deiminase 4 (PADI4) and citrullinated protein in synovial tissue of rheumatoid arthritis","volume":"44","author":"Chang","year":"2005","journal-title":"Rheumatology (Oxford)"},{"issue":"11","key":"10.1016\/j.phrs.2019.104354_bib0180","doi-asserted-by":"crossref","first-page":"3541","DOI":"10.1002\/art.22983","article-title":"Peptidyl arginine deiminase type 2 (PAD-2) and PAD-4 but not PAD-1, PAD-3, and PAD-6 are expressed in rheumatoid arthritis synovium in close association with tissue inflammation","volume":"56","author":"Foulquier","year":"2007","journal-title":"Arthritis Rheum."},{"issue":"5","key":"10.1016\/j.phrs.2019.104354_bib0185","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1136\/annrheumdis-2012-202958","article-title":"Bone loss before the clinical onset of rheumatoid arthritis in subjects with anticitrullinated protein antibodies","volume":"73","author":"Kleyer","year":"2014","journal-title":"Ann. Rheum. Dis."},{"issue":"1","key":"10.1016\/j.phrs.2019.104354_bib0190","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1186\/s13075-016-1116-9","article-title":"Anti-citrullinated protein antibodies and high levels of rheumatoid factor are associated with systemic bone loss in patients with early untreated rheumatoid arthritis","volume":"18","author":"Bugatti","year":"2016","journal-title":"Arthritis Res. Ther."},{"issue":"1","key":"10.1016\/j.phrs.2019.104354_bib0195","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1007\/s00223-017-0253-8","article-title":"Titer-dependent effect of anti-citrullinated protein antibodies on systemic bone mass in rheumatoid arthritis patients","volume":"101","author":"Orsolini","year":"2017","journal-title":"Calcif. Tissue Int."},{"issue":"6","key":"10.1016\/j.phrs.2019.104354_bib0200","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1136\/annrheumdis-2015-208093corr1","article-title":"Correction: identification of a novel chemokine-dependent molecular mechanism underlying rheumatoid arthritis-associated autoantibody-mediated bone loss","volume":"78","year":"2019","journal-title":"Ann. Rheum. Dis."},{"issue":"6","key":"10.1016\/j.phrs.2019.104354_bib0205","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1136\/annrheumdis-2019-215337","article-title":"Pathogenic effector functions of ACPA: where do we stand?","volume":"78","author":"Toes","year":"2019","journal-title":"Ann. Rheum. Dis."},{"issue":"4","key":"10.1016\/j.phrs.2019.104354_bib0210","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1359\/jbmr.081209","article-title":"Vitamin D status, parathyroid function, bone turnover, and BMD in postmenopausal women with osteoporosis: global perspective","volume":"24","author":"Kuchuk","year":"2009","journal-title":"J. Bone Miner. Res."},{"issue":"6","key":"10.1016\/j.phrs.2019.104354_bib0215","doi-asserted-by":"crossref","first-page":"R216","DOI":"10.1186\/ar3195","article-title":"Vitamin D deficiency in rheumatoid arthritis: prevalence, determinants and associations with disease activity and disability","volume":"12","author":"Rossini","year":"2010","journal-title":"Arthritis Res. Ther."},{"issue":"1","key":"10.1016\/j.phrs.2019.104354_bib0220","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0146351","article-title":"Serum vitamin D level and rheumatoid arthritis disease activity: review and meta-analysis","volume":"11","author":"Lin","year":"2016","journal-title":"PLoS One"},{"issue":"7","key":"10.1016\/j.phrs.2019.104354_bib0225","doi-asserted-by":"crossref","first-page":"2143","DOI":"10.1002\/art.22722","article-title":"Association between serum vitamin D metabolite levels and disease activity in patients with early inflammatory polyarthritis","volume":"56","author":"Patel","year":"2007","journal-title":"Arthritis Rheum."},{"issue":"23","key":"10.1016\/j.phrs.2019.104354_bib0230","doi-asserted-by":"crossref","first-page":"e7024","DOI":"10.1097\/MD.0000000000007024","article-title":"Vitamin D supplementation and disease activity in patients with immune-mediated rheumatic diseases: a systematic review and meta-analysis","volume":"96","author":"Franco","year":"2017","journal-title":"Medicine (Baltimore)"},{"issue":"7","key":"10.1016\/j.phrs.2019.104354_bib0235","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1111\/1756-185X.12770","article-title":"Role of vitamin D supplementation in improving disease activity in rheumatoid arthritis: an exploratory study","volume":"20","author":"Chandrashekara","year":"2017","journal-title":"Int. J. Rheum. Dis."},{"key":"10.1016\/j.phrs.2019.104354_bib0240","first-page":"1","article-title":"An exploratory study on the role of vitamin D supplementation in improving pain and disease activity in rheumatoid arthritis","author":"Adami","year":"2018","journal-title":"Mod. Rheumatol."},{"issue":"10","key":"10.1016\/j.phrs.2019.104354_bib0245","doi-asserted-by":"crossref","first-page":"2377","DOI":"10.1007\/s10067-017-3734-2","article-title":"In psoriatic arthritis Dkk-1 and PTH are lower than in rheumatoid arthritis and healthy controls","volume":"36","author":"Fassio","year":"2017","journal-title":"Clin. Rheumatol."},{"issue":"11","key":"10.1016\/j.phrs.2019.104354_bib0250","doi-asserted-by":"crossref","first-page":"3093","DOI":"10.1007\/s10067-018-4205-0","article-title":"Parathyroid hormone is a determinant of serum Dickkopf-1 levels in ankylosing spondylitis","volume":"37","author":"Orsolini","year":"2018","journal-title":"Clin. Rheumatol."},{"issue":"2","key":"10.1016\/j.phrs.2019.104354_bib0255","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/j.cmet.2008.07.001","article-title":"T cells potentiate PTH-induced cortical bone loss through CD40L signaling","volume":"8","author":"Gao","year":"2008","journal-title":"Cell Metab."},{"issue":"12","key":"10.1016\/j.phrs.2019.104354_bib0260","doi-asserted-by":"crossref","first-page":"1546","DOI":"10.1093\/rheumatology\/kei082","article-title":"Increase in bone mineral density of patients with rheumatoid arthritis treated with anti-TNF-alpha antibody: a prospective open-label pilot study","volume":"44","author":"Lange","year":"2005","journal-title":"Rheumatology (Oxford)"},{"issue":"2","key":"10.1016\/j.phrs.2019.104354_bib0265","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1136\/ard.2009.127787","article-title":"Stable bone mineral density in lumbar spine and hip in contrast to bone loss in the hands during long-term treatment with infliximab in patients with rheumatoid arthritis","volume":"70","author":"Eekman","year":"2011","journal-title":"Ann. Rheum. Dis."},{"issue":"3","key":"10.1016\/j.phrs.2019.104354_bib0270","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1007\/s10067-012-2128-8","article-title":"Infliximab improves bone metabolism and bone mineral density in rheumatoid arthritis and ankylosing spondylitis: a prospective 2-year study","volume":"32","author":"Dischereit","year":"2013","journal-title":"Clin. Rheumatol."},{"issue":"3","key":"10.1016\/j.phrs.2019.104354_bib0275","doi-asserted-by":"crossref","first-page":"189","DOI":"10.5152\/eurjrheum.2017.17006","volume":"4","author":"Toussirot","year":"2017","journal-title":"Eur. J. Rheumatol."},{"issue":"11","key":"10.1016\/j.phrs.2019.104354_bib0280","doi-asserted-by":"crossref","first-page":"1495","DOI":"10.1136\/ard.2005.044198","article-title":"Evaluation of bone mineral density, bone metabolism, osteoprotegerin and receptor activator of the NFkappaB ligand serum levels during treatment with infliximab in patients with rheumatoid arthritis","volume":"65","author":"Vis","year":"2006","journal-title":"Ann. Rheum. Dis."},{"issue":"10","key":"10.1016\/j.phrs.2019.104354_bib0285","doi-asserted-by":"crossref","first-page":"2996","DOI":"10.1002\/art.11292","article-title":"Early changes in bone metabolism in rheumatoid arthritis patients treated with infliximab","volume":"48","author":"Vis","year":"2003","journal-title":"Arthritis Rheum."},{"issue":"3","key":"10.1016\/j.phrs.2019.104354_bib0290","doi-asserted-by":"crossref","first-page":"R61","DOI":"10.1186\/ar2219","article-title":"A 1-year case-control study in patients with rheumatoid arthritis indicates prevention of loss of bone mineral density in both responders and nonresponders to infliximab","volume":"9","author":"Marotte","year":"2007","journal-title":"Arthritis Res. Ther."},{"key":"10.1016\/j.phrs.2019.104354_bib0295","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1196\/annals.1351.040","article-title":"Bone metabolism changes during anti-TNF-alpha therapy in patients with active rheumatoid arthritis","volume":"1069","author":"Seriolo","year":"2006","journal-title":"Ann. N. Y. Acad. Sci."},{"issue":"3","key":"10.1016\/j.phrs.2019.104354_bib0300","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1136\/ard.2007.076604","article-title":"Long-term effects of infliximab on bone and cartilage turnover markers in patients with rheumatoid arthritis","volume":"67","author":"Chopin","year":"2008","journal-title":"Ann. Rheum. Dis."},{"issue":"6","key":"10.1016\/j.phrs.2019.104354_bib0305","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1136\/ard.2007.073817","article-title":"Changes in bone mineral density in patients with recent onset, active rheumatoid arthritis","volume":"67","author":"Guler-Yuksel","year":"2008","journal-title":"Ann. Rheum. Dis."},{"issue":"5","key":"10.1016\/j.phrs.2019.104354_bib0310","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1007\/s00774-013-0535-9","article-title":"The limited effects of anti-tumor necrosis factor blockade on bone health in patients with rheumatoid arthritis under the use of glucocorticoid","volume":"32","author":"Okano","year":"2014","journal-title":"J. Bone Miner. Metab."},{"issue":"3","key":"10.1016\/j.phrs.2019.104354_bib0315","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1093\/rheumatology\/kes320","article-title":"Changes in bone mineral density during long-term treatment with adalimumab in patients with rheumatoid arthritis: a cohort study","volume":"52","author":"Krieckaert","year":"2013","journal-title":"Rheumatology (Oxford)"},{"issue":"5","key":"10.1016\/j.phrs.2019.104354_bib0320","doi-asserted-by":"crossref","first-page":"653","DOI":"10.3899\/jrheum.120397","article-title":"Periarticular bone gain at proximal interphalangeal joints and changes in bone turnover markers in response to tumor necrosis factor inhibitors in rheumatoid and psoriatic arthritis","volume":"40","author":"Szentpetery","year":"2013","journal-title":"J. Rheumatol."},{"issue":"12","key":"10.1016\/j.phrs.2019.104354_bib0325","doi-asserted-by":"crossref","first-page":"1898","DOI":"10.1136\/ard.2008.106484","article-title":"Bone loss in patients with active early rheumatoid arthritis: infliximab and methotrexate compared with methotrexate treatment alone. Explorative analysis from a 12-month randomised, double-blind, placebo-controlled study","volume":"68","author":"Haugeberg","year":"2009","journal-title":"Ann. Rheum. Dis."},{"issue":"6","key":"10.1016\/j.phrs.2019.104354_bib0330","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1007\/s00223-016-0114-x","article-title":"Short-term effects of TNF inhibitors on bone turnover markers and bone mineral density in rheumatoid arthritis","volume":"98","author":"Orsolini","year":"2016","journal-title":"Calcif. Tissue Int."},{"key":"10.1016\/j.phrs.2019.104354_bib0335","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1186\/1471-2474-15-289","article-title":"Generalized bone loss in early rheumatoid arthritis patients followed for ten years in the biologic treatment era","volume":"15","author":"Haugeberg","year":"2014","journal-title":"BMC Musculoskelet. Disord."},{"issue":"8914","key":"10.1016\/j.phrs.2019.104354_bib0340","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/S0140-6736(94)91049-9","article-title":"Generalised bone loss in patients with early rheumatoid arthritis","volume":"344","author":"Gough","year":"1994","journal-title":"Lancet"},{"issue":"6","key":"10.1016\/j.phrs.2019.104354_bib0345","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1002\/acr.22519","article-title":"Meta-analysis of tumor necrosis factor inhibitors and glucocorticoids on bone density in rheumatoid arthritis and ankylosing spondylitis trials","volume":"67","author":"Siu","year":"2015","journal-title":"Arthritis Care Res. (Hoboken)"},{"issue":"11","key":"10.1016\/j.phrs.2019.104354_bib0350","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1001\/archinte.165.11.1293","article-title":"Reduced loss of hand bone density with prednisolone in early rheumatoid arthritis: results from a randomized placebo-controlled trial","volume":"165","author":"Haugeberg","year":"2005","journal-title":"Arch. Intern. Med."},{"issue":"6","key":"10.1016\/j.phrs.2019.104354_bib0355","doi-asserted-by":"crossref","first-page":"R128","DOI":"10.1186\/ar2542","article-title":"Better Anti-Rheumatic Farmac OTSG. Impact of low-dose prednisolone on bone synthesis and resorption in early rheumatoid arthritis: experiences from a two-year randomized study","volume":"10","author":"Engvall","year":"2008","journal-title":"Arthritis Res. Ther."},{"issue":"2","key":"10.1016\/j.phrs.2019.104354_bib0360","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1007\/s10067-004-0989-1","article-title":"Bone mineral density in patients with early rheumatoid arthritis treated with corticosteroids","volume":"24","author":"Habib","year":"2005","journal-title":"Clin. Rheumatol."},{"issue":"4","key":"10.1016\/j.phrs.2019.104354_bib0365","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1385\/JCD:8:4:371","article-title":"Precision assessment and radiation safety for dual-energy X-ray absorptiometry: position paper of the International Society for Clinical Densitometry","volume":"8","author":"Baim","year":"2005","journal-title":"J. Clin. Densitom."},{"issue":"1","key":"10.1016\/j.phrs.2019.104354_bib0370","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1007\/s00198-018-4704-5","article-title":"European guidance for the diagnosis and management of osteoporosis in postmenopausal women","volume":"30","author":"Kanis","year":"2018","journal-title":"Osteoporos. Int."},{"issue":"9","key":"10.1016\/j.phrs.2019.104354_bib0375","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1007\/s10067-008-0870-8","article-title":"Reduction of urinary levels of pyridinoline and deoxypyridinoline and serum levels of soluble receptor activator of NF-kappaB ligand by etanercept in patients with rheumatoid arthritis","volume":"27","author":"Yasunori","year":"2008","journal-title":"Clin. Rheumatol."},{"key":"10.1016\/j.phrs.2019.104354_bib0380","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1016\/j.intimp.2018.12.050","article-title":"Inhibition of tumor necrosis factor-alpha (TNF-alpha) in patients with early rheumatoid arthritis results in acute changes of bone modulators","volume":"67","author":"Fassio","year":"2018","journal-title":"Int. Immunopharmacol."},{"issue":"6","key":"10.1016\/j.phrs.2019.104354_bib0385","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1093\/rheumatology\/kei280","article-title":"The effect of infliximab on bone metabolism markers in patients with rheumatoid arthritis","volume":"45","author":"Torikai","year":"2006","journal-title":"Rheumatology (Oxford)"},{"issue":"5","key":"10.1016\/j.phrs.2019.104354_bib0390","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1136\/ard.2007.076711","article-title":"Infliximab inhibits bone resorption by circulating osteoclast precursor cells in patients with rheumatoid arthritis and ankylosing spondylitis","volume":"67","author":"Gengenbacher","year":"2008","journal-title":"Ann. Rheum. Dis."},{"issue":"4","key":"10.1016\/j.phrs.2019.104354_bib0395","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1007\/s00223-016-0161-3","article-title":"Effects of TNF inhibitors on parathyroid hormone and wnt signaling antagonists in rheumatoid arthritis","volume":"99","author":"Adami","year":"2016","journal-title":"Calcif. Tissue Int."},{"issue":"7","key":"10.1016\/j.phrs.2019.104354_bib0400","doi-asserted-by":"crossref","first-page":"1744","DOI":"10.1002\/art.10388","article-title":"High levels of osteoprotegerin and soluble receptor activator of nuclear factor kappa B ligand in serum of rheumatoid arthritis patients and their normalization after anti-tumor necrosis factor alpha treatment","volume":"46","author":"Ziolkowska","year":"2002","journal-title":"Arthritis Rheum."},{"issue":"11","key":"10.1016\/j.phrs.2019.104354_bib0405","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1038\/nrrheum.2012.153","article-title":"Bone erosion in rheumatoid arthritis: mechanisms, diagnosis and treatment","volume":"8","author":"Schett","year":"2012","journal-title":"Nat. Rev. Rheumatol."},{"issue":"41","key":"10.1016\/j.phrs.2019.104354_bib0410","doi-asserted-by":"crossref","first-page":"6241","DOI":"10.2174\/1381612823666170713104431","article-title":"New strategies for the prevention and treatment of systemic and local bone loss; from pathophysiology to clinical application","volume":"23","author":"Fassio","year":"2017","journal-title":"Curr. Pharm. Des."},{"issue":"5","key":"10.1016\/j.phrs.2019.104354_bib0415","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1097\/BOR.0b013e328356d212","article-title":"Effects of anti-tumor necrosis factor alpha agents on bone","volume":"24","author":"Kawai","year":"2012","journal-title":"Curr. Opin. Rheumatol."},{"issue":"4","key":"10.1016\/j.phrs.2019.104354_bib0420","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1002\/jbmr.1489","article-title":"Effects of disease-modifying antirheumatic drugs on nonvertebral fracture risk in rheumatoid arthritis: a population-based cohort study","volume":"27","author":"Kim","year":"2012","journal-title":"J. Bone Miner. Res."},{"issue":"4","key":"10.1016\/j.phrs.2019.104354_bib0425","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1097\/RHU.0b013e3181a5679d","article-title":"Factors influencing fracture risk, T score, and management of osteoporosis in patients with rheumatoid arthritis in the Consortium of Rheumatology Researchers of North America (CORRONA) registry","volume":"15","author":"Coulson","year":"2009","journal-title":"J. Clin. Rheumatol."},{"issue":"2","key":"10.1016\/j.phrs.2019.104354_bib0430","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1136\/ard.2003.017780","article-title":"Bone mineral density in patients with rheumatoid arthritis treated with infliximab","volume":"64","author":"Vis","year":"2005","journal-title":"Ann. Rheum. Dis."},{"issue":"1","key":"10.1016\/j.phrs.2019.104354_bib0435","doi-asserted-by":"crossref","first-page":"183","DOI":"10.3349\/ymj.2013.54.1.183","article-title":"Influence of infliximab on cytokines network and markers of bone remodeling in rheumatoid arthritis patients","volume":"54","author":"Korczowska","year":"2013","journal-title":"Yonsei Med. J."},{"key":"10.1016\/j.phrs.2019.104354_bib0440","doi-asserted-by":"crossref","first-page":"453","DOI":"10.2147\/TCRM.S156350","article-title":"Effects of denosumab on bone metabolism and bone mineral density with anti-TNF inhibitors, tocilizumab, or abatacept in osteoporosis with rheumatoid arthritis","volume":"14","author":"Suzuki","year":"2018","journal-title":"Ther. Clin. Risk Manag."},{"issue":"Suppl. 3","key":"10.1016\/j.phrs.2019.104354_bib0445","doi-asserted-by":"crossref","first-page":"S233","DOI":"10.1186\/ar565","article-title":"The paradigm of IL-6: from basic science to medicine","volume":"4","author":"Naka","year":"2002","journal-title":"Arthritis Res."},{"issue":"1","key":"10.1016\/j.phrs.2019.104354_bib0450","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.cytogfr.2003.10.005","article-title":"IL-6, RANKL, TNF-alpha\/IL-1: interrelations in bone resorption pathophysiology","volume":"15","author":"Kwan Tat","year":"2004","journal-title":"Cytokine Growth Factor Rev."},{"issue":"1","key":"10.1016\/j.phrs.2019.104354_bib0455","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1002\/art.21537","article-title":"Interleukin-6 modulates production of T lymphocyte-derived cytokines in antigen-induced arthritis and drives inflammation-induced osteoclastogenesis","volume":"54","author":"Wong","year":"2006","journal-title":"Arthritis Rheum."},{"issue":"2","key":"10.1016\/j.phrs.2019.104354_bib0460","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1111\/cei.12201","article-title":"Anti-interleukin-6 receptor antibody prevents systemic bone mass loss via reducing the number of osteoclast precursors in bone marrow in a collagen-induced arthritis model","volume":"175","author":"Tanaka","year":"2014","journal-title":"Clin. Exp. Immunol."},{"issue":"3","key":"10.1016\/j.phrs.2019.104354_bib0465","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1016\/j.yexmp.2008.03.003","article-title":"Early effects of tocilizumab on bone and bone marrow lesions in a collagen-induced arthritis monkey model","volume":"84","author":"Kato","year":"2008","journal-title":"Exp. Mol. Pathol."},{"issue":"2","key":"10.1016\/j.phrs.2019.104354_bib0470","doi-asserted-by":"crossref","first-page":"89","DOI":"10.3325\/cmj.2016.57.89","article-title":"Interleukin 6\/Wnt interactions in rheumatoid arthritis: interleukin 6 inhibits Wnt signaling in synovial fibroblasts and osteoblasts","volume":"57","author":"Malysheva","year":"2016","journal-title":"Croat. Med. J."},{"issue":"1","key":"10.1016\/j.phrs.2019.104354_bib0475","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1002\/art.25053","volume":"62","author":"Garnero","year":"2010","journal-title":"Arthritis Rheum."},{"issue":"2","key":"10.1016\/j.phrs.2019.104354_bib0480","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.semarthrit.2012.01.004","article-title":"IL-6 receptor inhibition positively modulates bone balance in rheumatoid arthritis patients with an inadequate response to anti-tumor necrosis factor therapy: biochemical marker analysis of bone metabolism in the tocilizumab RADIATE study (NCT00106522)","volume":"42","author":"Karsdal","year":"2012","journal-title":"Semin. Arthritis Rheum."},{"issue":"9","key":"10.1016\/j.phrs.2019.104354_bib0485","doi-asserted-by":"crossref","first-page":"2669","DOI":"10.1007\/s00296-011-2021-9","article-title":"Osteoprotegerin expression in bone marrow by treatment with tocilizumab in rheumatoid arthritis","volume":"32","author":"Kanbe","year":"2012","journal-title":"Rheumatol. Int."},{"issue":"11","key":"10.1016\/j.phrs.2019.104354_bib0490","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0188454","article-title":"Tocilizumab potentially prevents bone loss in patients with anticitrullinated protein antibody-positive rheumatoid arthritis","volume":"12","author":"Chen","year":"2017","journal-title":"PLoS One"},{"issue":"4","key":"10.1016\/j.phrs.2019.104354_bib0495","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1016\/j.semarthrit.2013.07.008","article-title":"Effect of tocilizumab combined with methotrexate on circulating biomarkers of synovium, cartilage, and bone in the LITHE study","volume":"43","author":"Bay-Jensen","year":"2014","journal-title":"Semin. Arthritis Rheum."},{"issue":"2","key":"10.1016\/j.phrs.2019.104354_bib0500","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.jbspin.2014.10.015","article-title":"The effect of tocilizumab on bone mineral density, serum levels of Dickkopf-1 and bone remodeling markers in patients with rheumatoid arthritis","volume":"82","author":"Briot","year":"2015","journal-title":"Joint Bone Spine"},{"issue":"1","key":"10.1016\/j.phrs.2019.104354_bib0505","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1186\/s13075-016-1132-9","article-title":"Sarilumab plus methotrexate suppresses circulating biomarkers of bone resorption and synovial damage in patients with rheumatoid arthritis and inadequate response to methotrexate: a biomarker study of MOBILITY","volume":"18","author":"Boyapati","year":"2016","journal-title":"Arthritis Res. Ther."},{"issue":"6","key":"10.1016\/j.phrs.2019.104354_bib0510","first-page":"921","article-title":"Early effects of IL-6 receptor inhibition on bone homeostasis: a pilot study in women with rheumatoid arthritis","volume":"29","author":"Terpos","year":"2011","journal-title":"Clin. Exp. Rheumatol."},{"issue":"Suppl. 2","key":"10.1016\/j.phrs.2019.104354_bib0515","doi-asserted-by":"crossref","first-page":"570-","DOI":"10.1136\/annrheumdis-2017-eular.4534","article-title":"FRI0227 Sarilumab significantly suppresses circulating biomarkers of bone resorption and cardiovascular risk compared with adalimumab: biomarker analysis from the phase 3 monarch study","volume":"76","author":"Gabay","year":"2017","journal-title":"Ann. Rheum. Dis."},{"issue":"5","key":"10.1016\/j.phrs.2019.104354_bib0520","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1093\/rheumatology\/ket468","article-title":"The effect of tocilizumab on bone mineral density in patients with methotrexate-resistant active rheumatoid arthritis","volume":"53","author":"Kume","year":"2014","journal-title":"Rheumatology (Oxford)"},{"issue":"4","key":"10.1016\/j.phrs.2019.104354_bib0525","first-page":"239","article-title":"Effect of tocilizumab on fatigue and bone mineral density in patients with rheumatoid arthritis","volume":"20","author":"Abu-Shakra","year":"2018","journal-title":"Isr. Med. Assoc. J."},{"issue":"20","key":"10.1016\/j.phrs.2019.104354_bib0530","doi-asserted-by":"crossref","first-page":"1907","DOI":"10.1056\/NEJMoa035075","article-title":"Treatment of rheumatoid arthritis by selective inhibition of T-cell activation with fusion protein CTLA4Ig","volume":"349","author":"Kremer","year":"2003","journal-title":"N. Engl. J. Med."},{"issue":"11","key":"10.1016\/j.phrs.2019.104354_bib0535","doi-asserted-by":"crossref","first-page":"1603","DOI":"10.1136\/ard.2007.080713","article-title":"CTLA-4 directly inhibits osteoclast formation","volume":"67","author":"Axmann","year":"2008","journal-title":"Ann. Rheum. Dis."},{"issue":"235","key":"10.1016\/j.phrs.2019.104354_bib0540","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3007764","article-title":"T cell costimulation molecules CD80\/86 inhibit osteoclast differentiation by inducing the IDO\/tryptophan pathway","volume":"6","author":"Bozec","year":"2014","journal-title":"Sci. Transl. Med."},{"issue":"3","key":"10.1016\/j.phrs.2019.104354_bib0545","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/j.jaut.2005.09.020","article-title":"Prophylactic administration of abatacept prevents disease and bone destruction in a rat model of collagen-induced arthritis","volume":"25","author":"Kliwinski","year":"2005","journal-title":"J. Autoimmun."},{"key":"10.1016\/j.phrs.2019.104354_bib0550","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1111\/j.1749-6632.2009.05216.x","article-title":"Inhibition of antigen presentation and T cell costimulation blocks PTH-induced bone loss","volume":"1192","author":"Bedi","year":"2010","journal-title":"Ann. N. Y. Acad. Sci."},{"issue":"1","key":"10.1016\/j.phrs.2019.104354_bib0555","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1111\/nyas.13643","article-title":"CTLA-4Ig (abatacept) balances bone anabolic effects of T cells and Wnt-10b with antianabolic effects of osteoblastic sclerostin","volume":"1415","author":"Roser-Page","year":"2018","journal-title":"Ann. N. Y. Acad. Sci."},{"issue":"6","key":"10.1016\/j.phrs.2019.104354_bib0560","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1093\/rheumatology\/kex525","article-title":"Neutralization of CD40 ligand costimulation promotes bone formation and accretion of vertebral bone mass in mice","volume":"57","author":"Roser-Page","year":"2018","journal-title":"Rheumatology (Oxford)"},{"issue":"5","key":"10.1016\/j.phrs.2019.104354_bib0565","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1007\/s00296-017-3922-z","article-title":"Abatacept might increase bone mineral density at femoral neck for patients with rheumatoid arthritis in clinical practice: AIRTIGHT study","volume":"38","author":"Tada","year":"2018","journal-title":"Rheumatol. Int."},{"issue":"25","key":"10.1016\/j.phrs.2019.104354_bib0570","doi-asserted-by":"crossref","first-page":"2572","DOI":"10.1056\/NEJMoa032534","article-title":"Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis","volume":"350","author":"Edwards","year":"2004","journal-title":"N. Engl. J. Med."},{"issue":"11","key":"10.1016\/j.phrs.2019.104354_bib0575","doi-asserted-by":"crossref","first-page":"2022","DOI":"10.1136\/ard.2011.153312","article-title":"Cytokine mRNA profiling identifies B cells as a major source of RANKL in rheumatoid arthritis","volume":"70","author":"Yeo","year":"2011","journal-title":"Ann. Rheum. Dis."},{"issue":"35","key":"10.1016\/j.phrs.2019.104354_bib0580","doi-asserted-by":"crossref","first-page":"29851","DOI":"10.1074\/jbc.M112.377945","article-title":"Receptor activator of nuclear factor kappaB ligand (RANKL) protein expression by B lymphocytes contributes to ovariectomy-induced bone loss","volume":"287","author":"Onal","year":"2012","journal-title":"J. Biol. Chem."},{"issue":"12","key":"10.1016\/j.phrs.2019.104354_bib0585","doi-asserted-by":"crossref","first-page":"3067","DOI":"10.1007\/s00198-011-1607-0","article-title":"Suppression of bone turnover by B-cell depletion in patients with rheumatoid arthritis","volume":"22","author":"Wheater","year":"2011","journal-title":"Osteoporos. Int."},{"issue":"2","key":"10.1016\/j.phrs.2019.104354_bib0590","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1007\/s00296-010-1560-9","article-title":"Influence of Rituximab on markers of bone remodeling in patients with rheumatoid arthritis: a prospective open-label pilot study","volume":"31","author":"Hein","year":"2011","journal-title":"Rheumatol. Int."},{"issue":"1","key":"10.1016\/j.phrs.2019.104354_bib0595","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1136\/annrheumdis-2011-200198","article-title":"Rituximab abrogates joint destruction in rheumatoid arthritis by inhibiting osteoclastogenesis","volume":"71","author":"Boumans","year":"2012","journal-title":"Ann. Rheum. Dis."},{"issue":"8","key":"10.1016\/j.phrs.2019.104354_bib0600","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0201527","article-title":"Changes in bone density and bone turnover in patients with rheumatoid arthritis treated with rituximab, results from an exploratory, prospective study","volume":"13","author":"Wheater","year":"2018","journal-title":"PLoS One"},{"issue":"Suppl. 3","key":"10.1016\/j.phrs.2019.104354_bib0605","first-page":"714","article-title":"Variations in lumbar spine and femoral BMD after rituximab therapy in active rheumatoid arthritis","volume":"69","author":"Salvin","year":"2010","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.phrs.2019.104354_bib0610","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1186\/1476-9255-7-41","article-title":"Anti-inflammatory activity and neutrophil reductions mediated by the JAK1\/JAK3 inhibitor, CP-690,550, in rat adjuvant-induced arthritis","volume":"7","author":"Meyer","year":"2010","journal-title":"J. Inflamm. (Lond.)"},{"key":"10.1016\/j.phrs.2019.104354_bib0615","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1146\/annurev-med-051113-024537","article-title":"The JAK-STAT pathway: impact on human disease and therapeutic intervention","volume":"66","author":"O\u2019Shea","year":"2015","journal-title":"Annu. Rev. Med."},{"issue":"2","key":"10.1016\/j.phrs.2019.104354_bib0620","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1359\/jbmr.090724","article-title":"Gene expression profiling in monocytes and SNP association suggest the importance of the STAT1 gene for osteoporosis in both Chinese and Caucasians","volume":"25","author":"Chen","year":"2010","journal-title":"J. Bone Miner. Res."},{"issue":"5","key":"10.1016\/j.phrs.2019.104354_bib0625","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1016\/j.coi.2009.07.013","article-title":"Hyper-IgE syndrome","volume":"21","author":"Minegishi","year":"2009","journal-title":"Curr. Opin. Immunol."},{"issue":"3","key":"10.1016\/j.phrs.2019.104354_bib0630","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1016\/j.bone.2011.04.020","article-title":"Osteoblast\/osteocyte-specific inactivation of Stat3 decreases load-driven bone formation and accumulates reactive oxygen species","volume":"49","author":"Zhou","year":"2011","journal-title":"Bone"},{"issue":"8","key":"10.1016\/j.phrs.2019.104354_bib0635","doi-asserted-by":"crossref","first-page":"1461","DOI":"10.1093\/rheumatology\/kex258","article-title":"Effects of tofacitinib in early arthritis-induced bone loss in an adjuvant-induced arthritis rat model","volume":"57","author":"Vidal","year":"2018","journal-title":"Rheumatology (Oxford)"},{"issue":"11","key":"10.1016\/j.phrs.2019.104354_bib0640","doi-asserted-by":"crossref","first-page":"3531","DOI":"10.1002\/art.34649","article-title":"JAK inhibition with tofacitinib suppresses arthritic joint structural damage through decreased RANKL production","volume":"64","author":"LaBranche","year":"2012","journal-title":"Arthritis Rheum."},{"issue":"7","key":"10.1016\/j.phrs.2019.104354_bib0645","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0181126","article-title":"A Jak1\/2 inhibitor, baricitinib, inhibits osteoclastogenesis by suppressing RANKL expression in osteoblasts in vitro","volume":"12","author":"Murakami","year":"2017","journal-title":"PLoS One"}],"container-title":["Pharmacological Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1043661819310369?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1043661819310369?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,19]],"date-time":"2025-10-19T22:05:57Z","timestamp":1760911557000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1043661819310369"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,9]]},"references-count":129,"alternative-id":["S1043661819310369"],"URL":"https:\/\/doi.org\/10.1016\/j.phrs.2019.104354","relation":{},"ISSN":["1043-6618"],"issn-type":[{"value":"1043-6618","type":"print"}],"subject":[],"published":{"date-parts":[[2019,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Effects of biological and targeted synthetic DMARDs on bone loss in rheumatoid arthritis","name":"articletitle","label":"Article Title"},{"value":"Pharmacological Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.phrs.2019.104354","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"104354"}}